Key result
Higher glucose-albumin ratio linked to ~2.2-fold higher major cardiovascular events risk after anthracycline therapy.
Why the study?
The study aimed to investigate the clinical value of the glucose-albumin ratio in predicting the prognosis of cancer patients prescribed anthracycline-based chemotherapy.
Does an elevated glucose-albumin ratio predict major adverse cardiovascular events in cancer patients treated with anthracycline-based chemotherapy?
Cohort (n=18,700)
Yes
Does an elevated glucose-albumin ratio predict major adverse cardiovascular events in cancer patients treated with anthracycline-based chemotherapy?
Elevated glucose-albumin ratio serves as a strong, independent metabolic predictor of major adverse cardiovascular events and mortality in cancer patients receiving cardiotoxic anthracycline therapy.
Answers are grounded in this paper and cite their sources.
GAR elevation was associated with higher MACE risk after anthracyclines; leaves open whether it refines risk stratification in prospective cohorts.
AIMS: This study aimed to investigate the clinical value of the glucose-albumin ratio (GAR) in predicting the prognosis of cancer patients prescribed anthracycline-based chemotherapy. METHODS: We included cancer patients who underwent anthracycline-based chemotherapy, drawn from the population-based cohort Clinical Data Analysis Reporting System of Hong Kong between January 2000 and December 2019. Demographics, medical history, baseline laboratory, and metabolic indicators, including GAR, were collected. We employed random survival forests (RSF) with the variable importance (VIMP) method to rank the importance of these variables. Cox proportional hazards regression was used to assess the association between GAR levels and event risks. RESULTS: A total of 18,700 patients were included in the analysis. The top 2 factors for predicting overall cardiovascular event risk were GAR and fasting blood glucose (FBG). Our results revealed that a higher GAR was significantly associated with poorer cardiovascular prognosis in patients with cancer prescribed with anthracycline-based chemotherapy. Compared to the lowest quartile, higher GAR levels were significantly associated with increased risk of all-cause mortality, major adverse cardiovascular events, hospitalization of heart failure, and cardiovascular mortality regardless of the adjustments (all p trend < 0.001). CONCLUSION: GAR is a potential biomarker for predicting the prognosis of cancer patients undergoing anthracycline-based chemotherapy. Monitoring GAR levels before and during treatment may help identify patients at higher risk of adverse outcomes, facilitating personalized treatment strategies and improving clinical management.
No takes yet. Share an insight, caveat, or question.
Cheang et al. (2024) conducted a cohort in Cancer patients receiving anthracycline-based chemotherapy (n=18,700). Elevated glucose-albumin ratio (GAR) vs. Lowest quartile of glucose-albumin ratio (GAR) was evaluated on Major adverse cardiovascular events (MACE), comprising CVD mortality and hospitalization due to heart failure (HR 2.23, 95% CI 1.88-2.65, p=<0.001). Higher glucose-albumin ratio (highest quartile vs lowest quartile) increased the risk of major adverse cardiovascular events in cancer patients treated with anthracyclines.
Synapse has enriched 10 related papers. Consider them for comparative context: